Tempest Therapeutics
Brisbane, US · 6 known investors
Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications. Its pipeline includes a dual-target CD19/BCMA CAR structure and a CD7-targeted mRNA lipid nanoparticle CAR-T delivery platform, with lead candidate TPST-4003 planned for trials in myasthenia gravis and multiple sclerosis.
Founders & leadership
SB
Stephen BradyExecutive
MA
Matthew AngelExecutive
NM
Nicholas MaestasExecutive
TW
Thomas WoiwodeNamed on SEC filing
GN
Geoffrey NicholNamed on SEC filing
TW
Thomas W. DubenskyNamed on SEC filing
Board
CP
Christine PellizzariBoard director
RS
Ronit SimantovBoard director
MR
Michael RaabBoard director
Investors · 6
Funding
SEC filings, press & company announcements$21.1M disclosed across 3 of 4 rounds · 2022–2026
- Undisclosed amountregistered direct offeringNov 2025Source ↗
▶$4.1MraisedJun 2026 · 1 investors · BiotechnologyRule 506(b)
▶$4.1MraisedJun 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John David YeeDirector
- Matthew AngelExecutive Officer, Director
- Justin TrojanowskiExecutive Officer
- William Drake RicheyDirector
- Offering amount
- $4.1M
- Amount sold
- $4.1M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedApr 2026 · 3 investors · BiotechnologyRule 506(b)
▶$2MraisedApr 2026 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen BradyDirector
- Christine PellizzariDirector
- Matthew AngelExecutive Officer, Director
- Ronit SimantovDirector
- Michael RaabDirector
- Nicholas MaestasExecutive Officer
- Offering amount
- $2M
- Amount sold
- $2M
- Sales commissions
- $105K
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedMay 2022 · 2 investors · BiotechnologyRule 506(b)
▶$15MraisedMay 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen R. BradyExecutive Officer, Director
- Michael RaabDirector
- Ronit SimantovDirector
- Thomas WoiwodeDirector
- Geoffrey NicholDirector
- Thomas W. DubenskyExecutive Officer, Director
- Christine PellizzariDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Robinhood40 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha37 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwits32 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.
Companies competing with Tempest Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Tempest Therapeutics inks China in vivo CAR-T deal - TipRanks.comtipranks.com · Jul 2026Frequently asked questions
- What does Tempest Therapeutics do?
- Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications. Its pipeline includes a dual-target CD19/BCMA CAR structure and a CD7-targeted mRNA lipid nanoparticle CAR-T delivery platform, with lead candidate TPST-4003 planned for trials in myasthenia gravis and multiple sclerosis.
- Who are Tempest Therapeutics's investors?
- Tempest Therapeutics's investors include F-Prime Capital, LAV, Lilly Asia Ventures, New Enterprise Associates (NEA), Quan Capital, Roche Venture Fund.
- How much funding has Tempest Therapeutics raised?
- Tempest Therapeutics has disclosed $21.1M raised across 3 of its 4 known rounds.
- Where is Tempest Therapeutics headquartered?
- Tempest Therapeutics is headquartered in Brisbane, US.